AEON Biopharma, Inc. - 8-K Filing

AEON Biopharma received FDA feedback supporting streamlined development for ABP-450 biosimilar; plans IND submission in Q4 2026. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statement and Exhibits)

SEC EDGAR ·

Tickers: $AEON

Read the full article at SEC EDGAR

More Regulatory news